Immuneering (IMRX) Other financing activities (2022 - 2026)
Immuneering's (IMRX) quarterly Other financing activities came in at $10435.0 in Q1 2026, down 92.21% year-on-year from $133892.0 in Q1 2025, and up 100.04% quarter-over-quarter from -$24.6 million in Q4 2025.
Immuneering (IMRX) Other financing activities (2022 - 2026) Analysis & Trends
Immuneering's Other financing activities history runs 5 years deep, the most recent figure standing at $10435.0 for Q1 2026.
- On a quarterly basis, Other financing activities fell 92.21% year-over-year to $10435.0 in Q1 2026; TTM through Mar 2026 was $298453.0, a 51.78% decrease from a year earlier, with the FY2025 full-year figure at $421910.0, down 42.4% from the prior year.
- Other financing activities advanced to $10435.0 in Q1 2026 per IMRX's latest filing, from -$24.6 million in the prior quarter.
- Across five years, Other financing activities topped out at $24.9 million in Q3 2025 and bottomed at -$24.6 million in Q4 2025.
- The 5-year median for Other financing activities is $87995.0 (2022), against an average of $119376.2.
- Biggest YoY gain for Other financing activities was 7049.61% in 2025; the steepest drop was 6969.11% in 2025.
- Year by year, Other financing activities stood at $42098.0 in 2022, then tumbled by 81.39% to $7835.0 in 2023, then soared by 4466.76% to $357806.0 in 2024, then slumped by 6969.11% to -$24.6 million in 2025, then jumped by 100.04% to $10435.0 in 2026.
- Per Business Quant, the three latest IMRX Other financing activities figures stand at $10435.0 (Q1 2026), -$24.6 million (Q4 2025), and $24.9 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,435.00 |
| Mar 31, 2026 | 10,435.00 |
| Dec 31, 2025 | -24.58 Mn |
| Dec 31, 2025 | -24.58 Mn |
| Sep 30, 2025 | 24.87 Mn |
| Sep 30, 2025 | 24.87 Mn |
| Mar 31, 2025 | 133,892.00 |
| Mar 31, 2025 | 133,892.00 |
| Dec 31, 2024 | 357,806.00 |
| Dec 31, 2024 | 357,806.00 |
| Sep 30, 2024 | -357,806.00 |
| Sep 30, 2024 | -357,806.00 |
| Jun 30, 2024 | 484,993.00 |
| Jun 30, 2024 | 484,993.00 |
| Mar 31, 2024 | 247,465.00 |
| Mar 31, 2024 | 247,465.00 |
| Dec 31, 2023 | 7,835.00 |
| Dec 31, 2023 | 7,835.00 |
| Sep 30, 2023 | 437,003.00 |
| Sep 30, 2023 | 437,003.00 |